Diagnostic performance of high sensitivity troponin in non-ST elevation acute coronary syndrome

2020 ◽  
Vol 44 (2) ◽  
pp. 88-95
Author(s):  
J. Velilla Moliner ◽  
B. Gros Bañeres ◽  
J. Povar Marco ◽  
M. Santaló Bel ◽  
J. Ordoñez Llanos ◽  
...  
Author(s):  
Bakhtawar K. Mahmoodi ◽  
Niclas Eriksson ◽  
Gerrit J. A. Vos ◽  
Karina Meijer ◽  
Agneta Siegbahn ◽  
...  

Background The prothrombotic defect factor V Leiden (FVL) may confer higher risk of ST‐segment–elevation myocardial infarction (STEMI), compared with non–ST‐segment–elevation acute coronary syndrome, and may be associated with more myocardial necrosis caused by higher thrombotic burden. Methods and Results Patients without history of cardiovascular disease were selected from 2 clinical trials conducted in patients with acute coronary syndrome. FVL was defined as G‐to‐A substitution at nucleotide 1691 in the factor V (factor V R506Q) gene. Odds ratios were calculated for the association of FVL with STEMI adjusted for age and sex in the overall population and in the subgroups including sex, age (≥70 versus <70 years), and traditional cardiovascular risk factors. The peak biomarker levels (ie, creatine kinase‐myocardial band and high‐sensitivity troponin I or T) after STEMI were contrasted between FVL carriers and noncarriers. Because of differences in troponin assays, peak high‐sensitivity troponin levels were converted to a ratio scale. The prevalence of FVL mutation was comparable in patients with STEMI (6.0%) and non–ST‐segment–elevation acute coronary syndrome (5.8%). The corresponding sex‐ and age‐adjusted odds ratio was 1.06 (95% CI, 0.86–1.30; P =0.59) for the association of FVL with STEMI. Subgroup analysis did not show any differences. In patients with STEMI, neither the median peak creatine kinase‐myocardial band nor the peak high‐sensitivity troponin ratio showed any differences between wild‐type and FVL carriers ( P for difference: creatine kinase‐myocardial band=0.33; high sensitivity troponin ratio=0.54). Conclusions In a general population with acute coronary syndrome, FVL did not discriminate between a STEMI or non–ST‐segment–elevation acute coronary syndrome presentation and was unrelated to peak cardiac necrosis markers in patients with STEMI. Registration URL: https://www.clinicaltrials.gov ; Unique identifiers: NCT00391872 and NCT01761786.


Author(s):  
Sally J. Aldous ◽  
Chris M. Florkowski ◽  
Ian G. Crozier ◽  
Martin P. Than

AbstractMany papers evaluating high sensitivity troponin assays make the diagnosis of myocardial infarction based on conventional troponin assays in clinical use at the time of recruitment. Such analyses often do not show superiority of high sensitivity assays compared with contemporary assays meeting precision guidelines.Three hundred and twenty-two patients presenting to the emergency department between November 2006 and April 2007 for evaluation for acute coronary syndrome had serial (0 h and >6 h) bloods taken to compare troponin assays (Roche hsTnT, Abbott TnI, Roche TnT and Vitros TnI). The diagnosis of myocardial infarction was made using each troponin assay separately with which that same assay was analysed for diagnostic performance.The rate of myocardial infarction would be 38.9% using serial hsTnT, 31.3% using serial Abbott TnI, 27.1% using serial TnT and 26.4% using serial Vitros TnI. The baseline sensitivities (0 h) are 89.9% (85.2–93.3) for hsTnT, 77.9% (71.0–87.5) for Abbott TnI, 73.0% (65.6–78.7) for TnT and 86.8% (74.6–94.4%) for Vitros TnI. The specificities (peak 0 h and >6 h samples) are 93.1% (91.2–93.1) for hsTnT, 88.3% (86.5–88.3) for Abbott TnI, 92.2% (90.5–92.2) for TnT and 90.6% (70.1–90.6) for Vitros TnI.hsTnT has superior sensitivity for myocardial infarction than even assays at or near guideline precision requirements (Abbott and Vitros TnI). The specificity of hsTnT assay is not as poor as previous analyses suggest.


Sign in / Sign up

Export Citation Format

Share Document